AstraZeneca’s Asthma Drug Fails in ‘Smoker’s Lung’ Study
AstraZeneca (AZN.L) announced on Wednesday that its asthma treatment, Fasenra, failed to meet its primary goal in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD)—a major setback in efforts to address this serious lung condition.
The drugmaker stated that Fasenra did not significantly reduce the rate of COPD exacerbations compared to a placebo, and added that it will further analyze the full set of trial data to better understand the results.
Fasenra is the second best-selling medicine in AstraZeneca’s respiratory and immunology portfolio. It generated $920 million in sales in the first half of 2025, an 18% increase compared to the same period last year.
Sharon Bar, an executive at AstraZeneca, said, “COPD, which remains one of the leading causes of death worldwide, is a complex and heterogeneous disease. We are advancing other promising approaches in our pipeline to address the unmet needs of patients.”
COPD, often referred to as “smoker’s lung,” is also being targeted by AstraZeneca’s other treatments, including its triple-combination inhaler Breztri Aerosphere and the experimental therapy tozorakimab.
The patients enrolled in the Fasenra trial were current or former smokers who were receiving existing treatments for COPD and had experienced at least two flare-ups in the past year.
In addition to the COPD trial results, AstraZeneca announced that its rare disease drug, Safinelo, successfully achieved its primary endpoint in a late-stage study, significantly reducing disease activity in patients with systemic lupus erythematosus, a chronic autoimmune disorder.
Continuing the achievement of the journey of effectiveness and credibility of more than 10 years in the career of journalism, as a woman journalist, I am Serving as the founder, promoter and editor of DiaryTimes with the trust and support of all. My credible coverage may not have given a big shape to the numbers, but my journey presents articles that make you aware of the exact and meaningful situations of Himachal’s politics, ground issues related to the public, business, tourism and the difficult geographical conditions of the state and financial awareness. DiaryTimes, full of the experience of my precise editorial expertise, is awakening the flame of credible journalism among all of you, so that the eternal flame of meaningful change can be lit in the life of the people of the state and the atrocities being committed against the people can be brought to the fore, I am motivated for that. If even a small change comes with the power of my journalism and the whole world becomes a witness to that issues, then I will consider myself fortunate.
